ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$65.43 USD
-0.71 (-1.07%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $65.42 -0.01 (-0.02%) 4:28 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ANIP 65.43 -0.71(-1.07%)
Will ANIP be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?
Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
Other News for ANIP
Evaluating ANI Pharmaceuticals: Insights From 5 Financial Analysts
ANI Pharmaceuticals to Discuss First Quarter 2024 Financial Results on May 10, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals Financial Report: Key Insights Revealed
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
ANI Pharmaceuticals announces launch of Baclofen Oral Suspension